Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03222635 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prospective Endoscopic Follow-up of Patients With Submucosal and High Risk Mucosal Esophageal Adenocarcinoma

Study acronym: PREFER
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 19 to 20v5
  2. Lead sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) to Amsterdam UMCv4 Show 6 more changesShow less
    • Enrollment target: 141 to 225
    • Primary and study completion dates: Jul 25, 2025 to Jul 25, 2028
    • Study sites: 18 to 19
    • Study description expanded, about 7 words
    • Eligibility criteria shortened, about 3 words
    • Study title expanded, about 1 word
  3. Study sites: 14 to 18
    • Study description expanded, about 121 words
    • Eligibility criteria expanded, about 4 words
    v3
  4. Primary and study completion dates: Jul 25, 2024 to Jul 25, 2025v2 Show 4 more changesShow less
    • Primary endpoints revised (2)
    • Study sites: 9 to 14
    • Secondary endpoints revised (5)
    • Study description expanded, about 13 words
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Aim of this prospective multicenter study is to evaluate the safety of an endoscopic follow-up strategy in patients treated with endoscopic resection (ER) for submucosal or high-risk mucosal esophageal adenocarcinoma (T1bN0M0 or HR T1aN0M0 EAC).
Trial Details
NCT Number NCT03222635
Lead Sponsor Amsterdam UMC
Conditions
(from sponsor)		 Submucosal Esophageal Adenocarcinoma, Barrett Esophagus, High-risk Mucosal Esophageal Adenocarcinoma
Related terms Barrett Esophagus
Enrollment 225 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov